Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Daewoong’s high-dose Alvis approved for marketing
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 4, 2014 15:06:53
Daewoong got marketing approval for Alvis D, its double-strength Alvis, from the Ministry of Food and Drug Saftey on December 1.

Alvis D contains ranitidine 168mg, bismuth 200mg and sucralfate 600mg.

Daewoong developed Alvis D to defend its market share from generic versions of Alvis. It also rolled out its authorized generic drug of Alvis, which racked up 10 billion won last year.

Currently only Pharvis and Hanall got marketing approval for their generic version of Alvis, but more than ten pharmaceutical companies are ready to jump into the market through contracts.

Ahngook is also working on its double-strength generic version of Alvis. Industry experts said the market competition will get fiercer among Alvis, authorized generic versions, and high-dose Alvis.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com